Amgen Shares Jump on Strong Q2 Results and Product Momentum

Amgen Inc (NASDAQ:AMGN, XETRA:AMG) shares surged about 4% on Wednesday after the biotechnology company reported second-quarter 2026 results that exceeded Wall Street expectations.

The company's adjusted earnings per share reached $6.29 for the quarter, surpassing analyst estimates of roughly $5.60 to $5.62.

Revenue reached $10.05 billion, exceeding consensus expectations of about $9.40 billion.

Amgen reported a 10% year-over-year increase in total revenue to $10.1 billion, while product sales rose 9%, driven by higher volumes.

The company stated that 22 products delivered double-digit sales growth during the quarter, with 17 products now generating annualized sales of more than $1 billion based on second-quarter performance.

'Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales,' Amgen CEO Robert Bradway said.